3-[3-(pentanoyloxy)-2,2-bis[(pantanoyloxy)methyl]propoxyl]-2,2-bis[(pentanoyloxy)methyl]propyl pentanoate 3-{3-[(3,5,5-trimethylhexanoyl)oxy]-2,2-bis({[(3,5,5-trimethylhexanoyl)oxy]methyl}propoxy)-2,2-bis({[(3,5,5-trimethylhexanoyl)oxy]methyl}propyl 3,5,5-trimethylhexanoate

Genetic toxicity: in vitro

Administrative data

Endpoint:

in vitro gene mutation study in mammalian cells

Remarks:

Type of genotoxicity: gene mutation

Type of information:

migrated information: read-across from supporting substance (structural analogue or surrogate)

Adequacy of study:

key study

Study period:

26 Mar - 11 May 2010

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: see 'Remark'

Remarks:

GLP-Guideline study, tested with the source substance 15834-04-5. According to the ECHA guidance document “Practical guide 6: How to report read-across and categories (March 2010)”, the reliability was changed from RL1 to RL2 to reflect the fact that this study was conducted on a read-across substance.

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2010

Report date:

2010

Materials and methods

Test guideline

Test guideline 1

Qualifier:

according to guideline

Guideline:

OECD Guideline 476 (In Vitro Mammalian Cell Gene Mutation Test)

Deviations:

no

Test guideline 2

Qualifier:

according to guideline

Guideline:

EU Method B.17 (Mutagenicity - In Vitro Mammalian Cell Gene Mutation Test)

Deviations:

no

GLP compliance:

yes

Type of assay:

mammalian cell gene mutation assay

Test material

Test material information

Constituent 1

Reference substance name:

2,2-bis[[(1-oxopentyl)oxy]methyl]propane-1,3-diyl divalerate

EC Number:

239-937-7

EC Name:

2,2-bis[[(1-oxopentyl)oxy]methyl]propane-1,3-diyl divalerate

Cas Number:

15834-04-5

IUPAC Name:

3-(pentanoyloxy)-2,2-bis[(pentanoyloxy)methyl]propyl valerate (non-preferred name)

Details on test material:

- Name of test material (as cited in study report): Pentaerythritol tetravalerate
- Molecular formula (if other than submission substance): C25H44O8
- Molecular weight (if other than submission substance): 472.3 Da
- Smiles notation (if other than submission substance): O=C(OCC(COC(=O)CCCC)(COC(=O)CCCC)COC(=O)CCCC)CCCC
- InChl (if other than submission substance): 1S/C25H44O8/c1-5-9-13-21(26)30-17-25(18-31-22(27)14-10-6-2,19-32-23(28)15-11-7-3)20-33-24(29)16-12-8-4/h5-20H2,1-4H3
- Physical state: pale yellow liquid
- Analytical purity: > 80%
- Lot/batch No.: 0000392438
- Expiration date of the lot/batch: November 30th, 2011
- Storage condition of test material: RT in the dark
- Stability under test conditions: stable

Method

Target gene:

TK locus

Species / strain

Species / strain / cell type:

mouse lymphoma L5178Y cells

Details on mammalian cell type (if applicable):

- Type and identity of media: RPMI 1640 supplemented with 5% (v/v) heat-inactivated horse serum containing pen/strep (50 U/mL), 1 mM sodium pyruvate and 2 mM L-glutamine
- Properly maintained: yes
- Periodically "cleansed" against high spontaneous background: yes

Metabolic activation:

with and without

Metabolic activation system:

co-factor supplemented post-mitochondrial fraction (S9 mix), prepared from the livers of rats treated with phenobarbital and ß-naphthoflavone

Test concentrations with justification for top dose:

Dose range finding study
With and without S9 mix: 3, 10, 33, 100, 200 mg/mL
First experiment
With (8% v/v) and without S9 mix: 0.03, 0.1, 0.3, 1, 3, 10, 33, 100 µg/mL
Second experiment
With S9 mix (12% v/v): 0.03, 0.1, 0.3, 1, 3, 10, 33, 100 µg/mL
Without S9 mix: 0.1, 1, 3, 10, 33, 100, 200, 250 µg/mL

Vehicle / solvent:

- Vehicle(s)/solvent(s) used: DMSO

Controls

Controls 1

Untreated negative controls:

no

Negative solvent / vehicle controls:

yes

True negative controls:

no

Positive controls:

yes

Positive control substance:

methylmethanesulfonate

Remarks:

Migrated to IUCLID6: 15 and 5 µg/mL in DMSO, without S9

Controls 2

Untreated negative controls:

no

Negative solvent / vehicle controls:

yes

True negative controls:

no

Positive controls:

yes

Positive control substance:

cyclophosphamide

Remarks:

Migrated to IUCLID6: 7.5 µg/mL in Hanks´balanced salt solution, with S9

Details on test system and experimental conditions:

METHOD OF APPLICATION: in suspension

DURATION
- Exposure duration:
1st experiment: 3 h exposure with and without S9 mix
2nd experiment: 3 h exposure with S9 mix and 24 h exposure in the absence of S9-mix
- Expression time (cells in growth medium): Cells in the final suspension after treatment were counted with the coulter particle counter. For the expression of the mutant phenotype, the cells were separated by 2 centrifugation steps and cultures for 48 h after the treatment period. Cells were plated for the determination of the cloning efficiency and mutation frequency. For the determination of the mutation frequency cells were plated and incubated for 11-12 days. After that, cells were stained for 2 h by adding 0.5 mg/mL MTT (Sigma) to each well. The plates were scored for cloning efficiency and mutation frequency with the naked eye or with the microscope.

SELECTION AGENT (mutation assays): RPMI 1640 supplemented with 20% (v/v) heat-inactivated horse serum and 5 µg/mL trifluorothymidine (TFT)

DETERMINATION OF CYTOTOXICITY
- Method: relative total growth

Evaluation criteria:

There are several criteria for determining a positive result, such as a concentration-related, or a reproducible increase in mutant frequency. In addition to this criteria, any increase of the mutation frequency should be evaluated for its biological relevance including a comparison of the results with the historical control data range.

Statistics:

The cloning efficiency (CE) was determined as follows:
P(0)= Number of empty wells divided by the total number of wells
CE= P(0)/number of cells plated per well

Relative survival rate (RS): RS= [CE(test)/CE(control)] x 100
Relative total growth (RTG): RTG= RSG x RSday2 / 100
Suspension growth (SG): [Day 0 cell count/1.25x10E05] x [Day 1 cell count/1.25x10E05] x [Day 2 cell count]
Relative suspension growth (RSG): SG(test)/SG(control) x 100

RSday2= CEday2(test) / CEday2(control) x 100

The growth rate (GR) was calculated for the solvent control cultures:
- 3 h treatment: [Day 1 cell count/1.25x10E05] x [Day 2 cell count/1.25x10E05]
- 24 h treatment: [Day 0 cell count/1.25x10E05] x [Day 1 cell count/1.25x10E05] x [Day 2 cell count/1.25x10E05]

The mutation frequency was expressed as the number of mutants per 10E06 viable cells. The plating efficiencies of both mutant and viable cells (CE day2) in the same culture were determined and the mutation frequency (MF) was calculated as follows:

MF= {-ln P(0)/number of cells plated per well)/CE day2 x 10E-06

Small and large colony mutation frequencies were calculated in an identical manner.

Results and discussion

Test results

Species / strain:

mouse lymphoma L5178Y cells

Metabolic activation:

with and without

Genotoxicity:

negative

Cytotoxicity / choice of top concentrations:

no cytotoxicity, but tested up to precipitating concentrations

Remarks:

and above (precipitating concentration: 100 µg/mL, tested up to 250 µg/mL)

Vehicle controls validity:

valid

Untreated negative controls validity:

not examined

Positive controls validity:

valid

Additional information on results:

TEST-SPECIFIC CONFOUNDING FACTORS
- Precipitation: at and above 100 µg/mL

RANGE-FINDING/SCREENING STUDIES: Yes, cytotoxicity data was obtained by treating cells for 3 h and 24 h respectively with a number of increasing test substance concentrations. The highest concentration tested was 200 µg/mL due to poor solubility of the test substance. No toxicity was observed with and without metabolic activation up to and at the maximum dose level tested with 3 h incubation. 24 h incubation resulted in 64% relative suspension growth in the absence of metabolic activation.

COMPARISON WITH HISTORICAL CONTROL DATA: Yes, all controls were in the range of the historical controls.

Remarks on result:

other: all strains/cell types tested

Remarks:

Migrated from field 'Test system'.

Any other information on results incl. tables

Table 1: Experiment 1

Dose (µg/ml)	RSG (%)	CE day2 (%)	RS day2 (%)	RTG (%)	mutation frequency x 10^-6
					total
Without metabolic activation, 3 h treatment
SC1	100	94	100	100	89
SC2		108			73
0.03	98	101	100	98	63
0.1	92	99	98	90	83
0.3	111	102	101	112	58
1	107	98	97	104	64
3	110	101	100	110	83
10	98	99	98	96	83
33	98	110	109	106	90
100*	74	94	93	69	97
MMS	70	63	63	44	1022
With 8% (v/v) metabolic activation, 3 h treatment
SC1	100	77	100	100	82
SC2		84			87
0.03	96	90	112	107	71
0.1	92	104	129	119	60
0.3	80	108	135	108	55
1	93	105	131	121	69
3	97	90	112	109	65
10	95	84	104	99	71
33	93	81	101	94	91
100*	42	83	103	43	98
CP	20	37	47	9	1107

Table 2: Experiment 2

Dose (µg/ml)	RSG (%)	CE day2 (%)	RS day2 (%)	RTG (%)	mutation frequency x 10^-6
					total
Without metabolic activation, 24 h treatment
SC1	100	102	100	100	62
SC2		104			57
0.1	97	83	80	78	87
1	94	105	102	96	68
3	102	90	87	89	65
10	104	115	111	115	54
33	105	83	80	84	53
100*	102	98	95	97	55
200*	116	104	101	116	52
250*	112	108	105	118	51
MMS	80	81	79	63	631
With 12% (v/v) metabolic activation, 3 h treatment
SC1	100	77	100	100	60
SC2		91			84
0.03	116	58	69	81	108
0.1	97	80	95	93	86
0.3	94	80	95	90	76
1	99	81	97	96	88
3	102	89	106	108	71
10	104	86	103	106	73
33	119	86	103	122	83
100*	105	77	91	96	72
CP	31	54	64	20	814

RSG: Relative Suspension Growth; CE: Cloning efficiency; RS: Relative Survival; RTG: Relative Total Growth; SC: Solvent Control (DMSO); MMS: Methylmethansulfonate; CP: Cyclophosphamide

*: Precipitation of test substance

Applicant's summary and conclusion

Conclusions:

Interpretation of results (migrated information):
negative